US EditionLong-Term Outcomes Following CAR T Cell Therapy: What We Know so Far
- In the CARTITUDE-1 trial from July 2018 to October 2019, patients with relapsed/refractory multiple myeloma received a single cilta-cel infusion across multiple sites.
- Cilta-Cel, a CAR T-cell therapy targeting BCMA, was approved by the FDA in 2022 for heavily pretreated RRMM patients and extended in 2024 to those with at least one prior therapy.
- The trial enrolled 97 triple-class exposed RRMM patients who had three or more prior therapies, showing a 98% overall response rate and a 21.8-month median duration of response.
- Investigators observed that one-third of patients remained progression-free and treatment-free for five years, with 31 of 32 showing stringent complete response and no minimal residual disease.
- These findings suggest cilta-cel offers durable remission and potential curative outcomes for a subset of advanced multiple myeloma patients, prompting trials in earlier disease stages.
11 Articles
11 Articles
Long-term outcomes following CAR T cell therapy: what we know so far
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now an established treatment for patients with relapsed and/or refractory B cell lymphomas, B cell acute lymphoblastic leukaemia and multiple myeloma. At the time of this writing, over a decade of follow-up data are available from the initial patients who received CD19-targeted CAR T cells for B cell m…
CAR-T therapy, which has been available since last year through a collaboration between the Red Cross and Auxilio Mutuo Hospital, has left three patients on the island in complete remission.
Medical Xpress
Single-dose CAR-T therapy potentially curative in multiple myeloma
A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or refractory multiple myeloma remained in remission for at least five years following a single infusion of the CAR-T cell therapy cilta-cel.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
